Isabelle Lascombe

649 total citations
23 papers, 555 citations indexed

About

Isabelle Lascombe is a scholar working on Molecular Biology, Cancer Research and Surgery. According to data from OpenAlex, Isabelle Lascombe has authored 23 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 9 papers in Cancer Research and 5 papers in Surgery. Recurrent topics in Isabelle Lascombe's work include Cancer, Lipids, and Metabolism (8 papers), Peroxisome Proliferator-Activated Receptors (7 papers) and Wnt/β-catenin signaling in development and cancer (6 papers). Isabelle Lascombe is often cited by papers focused on Cancer, Lipids, and Metabolism (8 papers), Peroxisome Proliferator-Activated Receptors (7 papers) and Wnt/β-catenin signaling in development and cancer (6 papers). Isabelle Lascombe collaborates with scholars based in France, Switzerland and Germany. Isabelle Lascombe's co-authors include Sylvie Fauconnet, Hugues Bittard, Marie‐Laure Plissonnier, Walter Wahli, B Kantelip, G Adessi, Hervé Wallerand, É. Chabannes, Béatrice Desvergne and S. Bernardini and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Scientific Reports.

In The Last Decade

Isabelle Lascombe

23 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Isabelle Lascombe France 14 394 177 118 102 57 23 555
Stella Logotheti Germany 16 416 1.1× 198 1.1× 75 0.6× 212 2.1× 65 1.1× 33 671
Colleen H. Anna United States 16 647 1.6× 212 1.2× 46 0.4× 208 2.0× 67 1.2× 20 920
Mary Jo Pilat United States 12 407 1.0× 143 0.8× 69 0.6× 230 2.3× 68 1.2× 25 669
Wan-Ju Kim United States 15 559 1.4× 209 1.2× 37 0.3× 267 2.6× 112 2.0× 26 819
Yu‐Wei Chang Taiwan 15 271 0.7× 84 0.5× 69 0.6× 105 1.0× 44 0.8× 31 472
A. Kominea Greece 11 267 0.7× 122 0.7× 109 0.9× 212 2.1× 75 1.3× 12 640
Yunfei Wang United States 14 654 1.7× 222 1.3× 160 1.4× 172 1.7× 53 0.9× 21 887
Frédérique Fallone France 10 316 0.8× 223 1.3× 31 0.3× 185 1.8× 41 0.7× 12 574
Francesco Caiazza Ireland 12 295 0.7× 157 0.9× 47 0.4× 278 2.7× 77 1.4× 24 672
Amanda B. Parris United States 15 254 0.6× 96 0.5× 25 0.2× 126 1.2× 51 0.9× 22 409

Countries citing papers authored by Isabelle Lascombe

Since Specialization
Citations

This map shows the geographic impact of Isabelle Lascombe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Isabelle Lascombe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Isabelle Lascombe more than expected).

Fields of papers citing papers by Isabelle Lascombe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Isabelle Lascombe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Isabelle Lascombe. The network helps show where Isabelle Lascombe may publish in the future.

Co-authorship network of co-authors of Isabelle Lascombe

This figure shows the co-authorship network connecting the top 25 collaborators of Isabelle Lascombe. A scholar is included among the top collaborators of Isabelle Lascombe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Isabelle Lascombe. Isabelle Lascombe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lascombe, Isabelle, et al.. (2024). Concomitant decrease of E- and A-FABP expression predicts worse survival in urothelial bladder cancer patients. Scientific Reports. 14(1). 15390–15390. 2 indexed citations
2.
3.
Élie-Caille, Céline, et al.. (2020). Molecular and nanoscale evaluation of N-cadherin expression in invasive bladder cancer cells under control conditions or GW501516 exposure. Molecular and Cellular Biochemistry. 471(1-2). 113–127. 14 indexed citations
4.
Lascombe, Isabelle, Franck Monnien, Hugues Bittard, et al.. (2018). Down-regulation of A-FABP predicts non-muscle invasive bladder cancer progression: investigation with a long term clinical follow-up. BMC Cancer. 18(1). 1239–1239. 18 indexed citations
5.
Plissonnier, Marie‐Laure, Sylvie Fauconnet, Hugues Bittard, et al.. (2017). Cell death and restoration of TRAIL-sensitivity by ciglitazone in resistant cervical cancer cells. Oncotarget. 8(64). 107744–107762. 15 indexed citations
6.
Fauconnet, Sylvie, et al.. (2016). Apoptotic effect of the selective PPARβ/δ agonist GW501516 in invasive bladder cancer cells. Tumor Biology. 37(11). 14789–14802. 8 indexed citations
7.
Lascombe, Isabelle, et al.. (2013). The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. Cellular Signalling. 26(2). 433–443. 6 indexed citations
8.
Plissonnier, Marie‐Laure, Sylvie Fauconnet, Hugues Bittard, & Isabelle Lascombe. (2010). Insights on distinct pathways of thiazolidinediones (PPARγ ligand)‐promoted apoptosis in TRAIL‐sensitive or ‐resistant malignant urothelial cells. International Journal of Cancer. 127(8). 1769–1784. 18 indexed citations
9.
Lascombe, Isabelle, et al.. (2008). A‐FABP, a candidate progression marker of human transitional cell carcinoma of the bladder, is differentially regulated by PPAR in urothelial cancer cells. International Journal of Cancer. 124(8). 1820–1828. 59 indexed citations
10.
Wallerand, Hervé, Ying Cai, Zev A. Wainberg, et al.. (2008). Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines. Urologic Oncology Seminars and Original Investigations. 28(2). 180–188. 35 indexed citations
11.
Clere, Nicolas, Laurent Bermont, Sylvie Fauconnet, et al.. (2007). The human papillomavirus type 18 E6 oncoprotein induces Vascular Endothelial Growth Factor 121 (VEGF121) transcription from the promoter through a p53-independent mechanism. Experimental Cell Research. 313(15). 3239–3250. 27 indexed citations
12.
Lascombe, Isabelle, et al.. (2006). Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors.. HAL (Le Centre pour la Communication Scientifique Directe). 2 indexed citations
13.
Lascombe, Isabelle, Sylvie Fauconnet, Frédéric Mauny, et al.. (2006). Expression of E-Cadherin and α-,β-,γ-Catenins in Patients With Bladder Cancer. American Journal of Clinical Pathology. 125(1). 119–126. 46 indexed citations
14.
Lascombe, Isabelle, Sylvie Fauconnet, S. Bernardini, et al.. (2006). N-Cadherin as a Novel Prognostic Marker of Progression in Superficial Urothelial Tumors. Clinical Cancer Research. 12(9). 2780–2787. 91 indexed citations
15.
Fauconnet, Sylvie, Isabelle Lascombe, É. Chabannes, et al.. (2002). Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer Cells. Journal of Biological Chemistry. 277(26). 23534–23543. 95 indexed citations
16.
Lascombe, Isabelle, et al.. (2000). Estrogenic activity assessment of environmental chemicals using in vitro assays: identification of two new estrogenic compounds.. Environmental Health Perspectives. 108(7). 621–629. 50 indexed citations
17.
Lascombe, Isabelle, et al.. (2000). Estrogenic Activity Assessment of Environmental Chemicals Using in Vitro Assays: Identification of Two New Estrogenic Compounds. Environmental Health Perspectives. 108(7). 621–621. 4 indexed citations
18.
Lascombe, Isabelle, et al.. (1998). ERE environment- and cell type-specific transcriptional effects of estrogen in normal endometrial cells. Molecular and Cellular Endocrinology. 139(1-2). 153–160. 2 indexed citations
19.
Lascombe, Isabelle, et al.. (1996). Gene Transfer into Subcultured Endometrial Cells Using Lipofection. BioTechniques. 20(1). 88–91. 14 indexed citations
20.
Ordener, Catherine, et al.. (1996). Differential EGF action on nuclear protooncogenes in human endometrial carcinoma RL95-2 cells.. PubMed. 16(1). 401–6. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stella Logotheti Breakdown of academic impact, for papers by Colleen H. Anna Breakdown of academic impact, for papers by Mary Jo Pilat Breakdown of academic impact, for papers by Wan-Ju Kim Breakdown of academic impact, for papers by Yu‐Wei Chang Breakdown of academic impact, for papers by A. Kominea Breakdown of academic impact, for papers by Yunfei Wang Breakdown of academic impact, for papers by Frédérique Fallone Breakdown of academic impact, for papers by Francesco Caiazza Breakdown of academic impact, for papers by Amanda B. Parris
Rankless by CCL
2026